Asset Details
Do you wish to reserve the book?
Dexmedetomidine: A Review of Its Use for Sedation in the Intensive Care Setting
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Dexmedetomidine: A Review of Its Use for Sedation in the Intensive Care Setting
Do you wish to request the book?
Dexmedetomidine: A Review of Its Use for Sedation in the Intensive Care Setting
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Dexmedetomidine: A Review of Its Use for Sedation in the Intensive Care Setting
2015
Overview
Dexmedetomidine (Dexdor
®
) is a highly selective α
2
-adrenoceptor agonist. It has sedative, analgesic and opioid-sparing effects and is suitable for short- and longer-term sedation in an intensive care setting. In the randomized, double-blind, multicentre MIDEX and PRODEX trials, longer-term sedation with dexmedetomidine was noninferior to midazolam and propofol in terms of time spent at the target sedation range, as well as being associated with a shorter time to extubation than midazolam or propofol, and a shorter duration of mechanical ventilation than midazolam. Patients receiving dexmedetomidine were also easier to rouse, more co-operative and better able to communicate than patients receiving midazolam or propofol. Dexmedetomidine had beneficial effects on delirium in some randomized, controlled trials (e.g. patients receiving dexmedetomidine were less likely to experience delirium than patients receiving midazolam, propofol or remifentanil and had more delirium- and coma-free days than patients receiving lorazepam). Intravenous dexmedetomidine had an acceptable tolerability profile; hypotension, hypertension and bradycardia were the most commonly reported adverse reactions. In conclusion, dexmedetomidine is an important option for sedation in the intensive care setting.
Publisher
Springer International Publishing,Springer Nature B.V
Subject
/ Conscious Sedation - methods
/ Delirium
/ Dexmedetomidine - adverse effects
/ Dexmedetomidine - pharmacokinetics
/ Dexmedetomidine - pharmacology
/ Dexmedetomidine - therapeutic use
/ Humans
/ Hypnotics and Sedatives - adverse effects
/ Hypnotics and Sedatives - pharmacokinetics
/ Hypnotics and Sedatives - pharmacology
/ Hypnotics and Sedatives - therapeutic use
/ Medicine
/ Plasma
